TNF Pharmaceuticals, Inc. Asset Resilience Ratio

Latest as of June 2025: 21.02%

TNF Pharmaceuticals, Inc. asset resilience ratio. TNF Pharmaceuticals, Inc. (TNFA) has an Asset Resilience Ratio of 21.02% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TNFA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$3.61 Million
Cash + Short-term Investments

Total Assets

$17.15 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of TNF Pharmaceuticals, Inc. (2014–2024)

Asset resilience ratio of TNF Pharmaceuticals, Inc. from 2014 to 2024. This chart shows how TNF Pharmaceuticals, Inc.'s Asset Resilience Ratio has changed over time. Read TNFA total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down TNF Pharmaceuticals, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TNFA current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $3.61 Million 21.02%
Total Liquid Assets $3.61 Million 21.02%

Asset Resilience Insights

  • Good Liquidity Position: TNF Pharmaceuticals, Inc. maintains a healthy 21.02% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

TNF Pharmaceuticals, Inc. Industry Peers by Asset Resilience Ratio

Compare TNF Pharmaceuticals, Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

TNF Pharmaceuticals, Inc. Asset Resilience Ratio by Year (2014–2024)

TNF Pharmaceuticals, Inc. asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for TNF Pharmaceuticals, Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 38.96% $8.35 Million $21.42 Million +26.41pp
2023-12-31 12.55% $2.24 Million $17.86 Million -10.75pp
2022-12-31 23.30% $4.09 Million $17.54 Million -21.04pp
2021-12-31 44.34% $11.00 Million $24.81 Million -1.03pp
2020-12-31 45.38% $16.72 Million $36.84 Million -38.81pp
2019-12-31 84.19% $9.16 Million $10.88 Million +16.65pp
2018-12-31 67.54% $5.27 Million $7.81 Million +13.87pp
2017-12-31 53.67% $5.01 Million $9.34 Million +52.69pp
2016-12-31 0.98% $50.00K $5.09 Million -47.68pp
2015-12-31 48.66% $4.03 Million $8.27 Million -6.98pp
2014-12-31 55.64% $9.26 Million $16.65 Million --
pp = percentage points

About TNF Pharmaceuticals, Inc.

NASDAQ:TNFA USA Biotechnology
Market Cap
$6.80 Million
Market Cap Rank
#27864 Global
#5749 in USA
Share Price
$3.68
Change (1 day)
+0.00%
52-Week Range
$3.68 - $3.68
All Time High
$42393.60
About

Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more